Wednesday, November 18, 2026
28.3 C
Bengaluru

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers over poor hygiene, expired materials, and unapproved ingredients—and issuing a fresh show-cause notice to Red Bull over its "energy drink" label—the compliance net is tightening fast. Between September 1 and November 5 alone, 56,431 food establishments were inspected nationwide.

For far too long, a segment of the market treated FSSAI licensing as a low-barrier shortcut to bypass stringent CDSCO drug standards while making aggressive clinical claims. That playbook is now a liability.

In the latest MedicinMan Intelligence Report (MIR), I examine what this regulatory reckoning means for India's nutraceutical ecosystem:

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” đź’Š

India has world-scale formulation capability, yet the chemistry beneath...

Topics

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” đź’Š

India has world-scale formulation capability, yet the chemistry beneath...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...
spot_img

Related Articles

spot_imgspot_img